RxDoctor Payments Data

Arti Pandey, MD

Internal Medicine · Tuscaloosa, ALNPI 1871586966

Payments from drug & device makers

$912in general payments, 2019–2025

Across 60 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$198
  • Novo Nordisk$184
  • Novartis$166
  • Abbott$69
  • Boehringer Ingelheim$68
  • Sanofi-aventis U.S. LLC$56
  • plus $171 from 6 others

What the payments were for

  • Food & beverage$63470%
  • Education$27830%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$912 in reported general payments places this provider in the 60th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$49,899
Medicare patients
122
Services billed
736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide124$169,128
JardianceEmpagliflozin171$164,564
MounjaroTirzepatide99$134,946
EliquisApixaban118$95,797
FarxigaDapagliflozin Propanediol46$44,043
TrulicityDulaglutide30$41,599
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$39,119
MyrbetriqMirabegron35$21,642
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog28$21,360
Sevelamer Hcl11$21,119
LinzessLinaclotide17$20,964
XareltoRivaroxaban26$20,017
Repatha SureclickEvolocumab12$18,377
EntrestoSacubitril/Valsartan28$18,352
JanuviaSitagliptin Phosphate14$16,372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$12$176,546129 claims
Novo NordiskOzempic$184$169,128124 claims
Boehringer IngelheimJardiance$68$164,564171 claims
AstraZenecaFarxiga, Breztri Aerosphere$24$59,54461 claims
AbbVieLinzess, Synthroid$52$23,60547 claims
Astellas Pharma US IncMyrbetriq$198$21,64235 claims
NovartisEntresto$166$18,35228 claims
MerckJanuvia$19$16,37214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →